Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIANGLE: Ibrutinib in Mantle Cell Lymphoma
NCT02858258Phase 3Recruiting
- Start
- Jul 2016
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of ibrutinib in mantle cell lymphoma (MCL). Started Jul 2016; status: recruiting.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02858258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858258.